



**REGISTERED OFFICE**

**GRANULES INDIA LTD.**, 2nd Floor, 3rd Block, My Home Hub,  
Madhapur, Hyderabad - 500 081, Telangana, INDIA.  
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com  
CIN: L24110TG1991PLC012471

**Dated August 21, 2018**

To,  
National Stock Exchange of India Limited,  
BSE Limited  
Symbol: GRANULES Scrip Code: 532482

**Sub: Received approval for ANDA filed by Granules India Limited.**

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir,

The US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules India Limited for Ranitidine Tablets USP, 150 mg and 150 mg Cool Mint (OTC). The approved ANDA is the bioequivalent to Reference Listed Drug (RLD) of Maximum Strength Zantac Tablets, 150 mg, of Sanofi-aventis U.S. LLC. Granules India Limited intends to commercialise this product shortly.

This is for your information and dissemination to the members

Thanking you.

Yours faithfully

**FOR GRANULES INDIA LIMITED**

*T. Chaitanya*  
  
**CHAITANYA TUMMALA**  
**COMPANY SECRETARY**  
**COMPLIANCE OFFICER**